1	Saliva as an alternative sample type for detection of pneumococcal carriage in young children		
2			
3	Anne L. Wyllie <sup>1,2#</sup> , Nynke Y. Rots <sup>3</sup> , Alienke J. Wijmenga-Monsuur <sup>3</sup> , Marlies A. van Houten <sup>4</sup> , Elisabeth		
4	A.M. Sanders <sup>1,3</sup> , and Krzysztof Trzciński <sup>1*</sup>		
5			
6	<sup>1</sup> Paediatric Immunology and Infectious Diseases, Wilhelmina Children's Hospital, University Medical		
7	Center Utrecht, Utrecht, the Netherlands; <sup>2</sup> Epidemiology of Microbial Diseases, Yale School of Public		
8	Health, New Haven, Connecticut, USA; <sup>3</sup> Centre for Infectious Disease Control, National Institute for		
9	Public Health and the Environment (RIVM), Bilthoven, the Netherlands; <sup>4</sup> Spaarne Gasthuis Academie,		
10	Spaarne Gasthuis, Hoofddorp, the Netherlands.		
11			
12	*corresponding author		
13	Yale School of Public Health		
14	60 College St		
15	New Haven		
16	CT 06511		
17	USA		
18	Phone: +1-203-781-6942		
19	e-mail: anne.wyllie@yale.edu		
20			
21	Keywords: Streptococcus pneumoniae, streptococci, carriage, diagnostic detection, saliva		
22			
23			

# 24 ABSTRACT (267 words)

In children, the gold standard for the detection of pneumococcal carriage is conventional culture of a nasopharyngeal swab. Saliva, however, has a history as one of the most sensitive methods for surveillances on pneumococcal colonisation and has recently been shown to improve carriage detection in older age groups. Here, we compared the sensitivity of nasopharyngeal and saliva samples from PCV7-vaccinated 24-month-old children for pneumococcal carriage detection using conventional and molecular diagnostic methods.

31

Nasopharyngeal and saliva samples were collected from 288 24-month-old children during the
autumn/winter, 2012/2013. All samples were first processed by conventional diagnostic techniques.
Next, DNA extracted from all plate growth was tested by qPCR for the presence of pneumococcal
genes *piaB* and *lytA* and a subset of serotypes.

36

37 By culture, 164/288 (57%) nasopharyngeal swabs tested positive for pneumococcus, but detection 38 was not possible from saliva due to abundant polymicrobial growth on culture-plates. Molecular 39 methods increased the number of children pneumococci-positive to 172/288 (60%) when testing 40 culture-enriched saliva and to 212/288 (73%) when testing nasopharyngeal samples. Altogether, by 41 molecular methods 239/288 (83%) infants were positive, with qPCR-based carriage detection of 42 culture-enriched nasopharyngeal swabs significantly detecting more carriers compared to either 43 conventional culture (p<0.001) or qPCR-detection of saliva (p<0.001). However, 27/240 (11%) 44 carriers were positive only in saliva, significantly contributing to the overall number of carriers 45 detected (p < 0.01).

46

While testing nasopharyngeal swabs with qPCR proved most sensitive for pneumococcal detection in infants, saliva sampling could be considered as complementary to provide additional information on carriage and serotypes which may not be detected in the nasopharynx and may be particularly useful in longitudinal studies, requiring repeated sampling events.

### 52 INTRODUCTION (399 words, total 2,011)

53 The human nasopharynx is considered the primary niche of Streptococcus pneumoniae, with 54 colonisation occasionally progressing to pneumococcal disease. Disease manifestations include respiratory infections such as otitis media or pneumonia, or invasive pneumococcal disease (IPD) 55 such as bacteraemia or sepsis with or without meningitis<sup>1</sup>. Current vaccination strategies are targeted 56 57 towards the polysaccharide capsule, which is considered the primary pneumococcal virulence factor<sup>2</sup>. With over 100 known capsular types (serotypes)<sup>3</sup>, current vaccination coverage is limited to either a 58 59 maximum of 20 serotypes included in the conjugated polysaccharide vaccines (PCVs) or 23 60 serotypes for the polysaccharide vaccine (PPSV23). PCV-vaccination of children (the key transmitters 61 of pneumococcus) not only protects against vaccine-serotype (VT) disease, but also against carriage 62 of VT strains. Moreover, PCVs lead to herd protection in other age groups, most importantly, by reducing VT-disease in older adults<sup>1,4-12</sup>. However, the gap left after VT-eradication from carriage in 63 children has been almost completely filled by emerging non-vaccine serotypes (NVTs)<sup>12-14</sup>. This 64 65 serotype replacement<sup>10</sup>, is eroding the benefits of vaccination to various extents across all age 66 groups, especially in older adults with increasing serotype replacement in diseases like pneumonia and IPD<sup>6,15,16</sup>. 67

68

69 For any strategy aiming to prevent pneumococcal disease, knowledge on pneumococcus reservoirs in 70 the population is essential and surveillance of carriage can provide data on vaccine effects before any 71 impact can be observed in disease<sup>17</sup>. Pneumococcal carriage detection has been instrumental in 72 monitoring the impact of vaccination against pneumococcal disease. The gold standard method for 73 carriage detection is conventional culture of a nasopharyngeal swab with an additional oropharyngeal swab recommended to improve the sensitivity of detection in adults<sup>18</sup>. Historical records from the pre-74 75 antibiotic era however, reported high carriage rates ranging between 39% and 54% across all ages, 76 when oral (saliva) samples were tested with sensitive animal inoculation method<sup>19-21</sup>. This suggested to us that sampling of the oral niche might increase carriage detection<sup>22</sup>. In line with this, we and 77 78 others have demonstrated the potential of molecular methods for increased pneumococcal detection in older age groups when oropharyngeal swabs<sup>23-26</sup> or saliva samples were tested alongside 79 nasopharyngeal swabs<sup>22,23</sup>. 80

Since young children are typically the focus of surveillance on pneumococcal carriage prior to or following updated vaccination strategies, we explored the sensitivity of culture and molecular methods for pneumococcal carriage detection in nasopharyngeal swabs and saliva samples collected from 24month-olds to investigate whether nasopharyngeal sampling was also under detecting carriage prevalence in this population.

87

#### 88 METHODS AND MATERIALS

**Study design.** Nasopharyngeal swabs were collected in a prospective cross-sectional study conducted in the Netherlands during the autumn/winter season of 2012/2013 from 330 PCV7vaccinated 24-month-old children<sup>14,27</sup>. Detailed descriptions of the study population and primary results for pneumococcal carriage detection in these nasopharyngeal samples were reported on previously<sup>14,27</sup> and in the current study, were analysed together with saliva samples which were also collected, as described below.

95

The study was approved by METC Noord-Holland (NL40288.094.12)<sup>14</sup> and conducted in accordance
with the European Statements for Good Clinical Practice and the declaration of Helsinki of the World
Health Medical Association. Written informed consent was obtained from all parents.

99

**Collection of saliva samples.** At time of nasopharyngeal sample collection<sup>14</sup>, a saliva sample was 100 101 also collected from each PCV7-vaccinated 24-month-old child. Prior to sample collection, informed 102 consent was obtained from both parents/caregivers, with saliva collection also approved by METC 103 Noord-Holland (NL40288.094.12)<sup>14</sup>. Briefly, a saliva collection sponge (Oracol®, Malvern Medical 104 Developments, Worcester, United Kingdom) was placed in the front part of the child's mouth for approximately one minute until saturated with saliva<sup>28</sup>. The wet sponge was then placed into a 5 ml 105 106 syringe and the stick was withdrawn through the narrow opening, leaving only the sponge inside the 107 syringe. Using the plunger, the sponge was compressed, and the saliva was transferred to 2 ml 108 cryovials prefilled with 0.1 ml of 50% glycerol water solution. Samples were transported to the 109 diagnostic lab on dry ice, stored at -80°C, thawed in batches and 100 µl of saliva cultured on 110 Columbia agar with 7% defibrinated sheep blood and gentamicin 5 mg/l, the medium selective for pneumococcus, as previously described<sup>14,23</sup>. All bacterial growth was harvested from all culture-plates 111

into Brain Heart Infusion Broth (Oxoid, Badhoevedorp, the Netherlands) supplemented with 10% glycerol and stored frozen at -80°C<sup>22</sup>. These samples were considered culture-enriched for pneumococcus. Later, DNA was extracted from 200 µl of culture-enriched saliva samples as previously described<sup>22</sup>.

116

117 **Pneumococcal carriage and serotype detection.** DNA templates from culture-enriched saliva were 118 first tested for the presence of two pneumococcal-specific genes  $piaB^{24,27}$  and  $lytA^{29}$ . Samples were 119 classified as positive for pneumococcus when  $C_T$  values for both targeted genes were <40<sup>22,23,25,26</sup>.

120

121 Regardless of outcome of *piaB* and *lytA* qPCR-testing, all saliva samples from children were tested in 122 qPCR for the presence of sequences specific for pneumococcal serotypes/serogroups 1, 3, 6A/B/C/D, 123 7A/F, 8, 9A/N/V, 10A/B, 12A/B/F, 14, 15A/B/C, 19A, 20, 23F, 33A/F/37<sup>30</sup>, 11A/D, 16F, 18B/C and 124  $19F^{31}$ . Samples were classified as positive for pneumococcal serotype/serogroup when C<sub>7</sub> values for 125 targeted genes were <40.

126

127 **Statistics.** Statistical analyses were conducted using GraphPad Prism v5.0 (GraphPad Software, San 128 Diego, CA, USA). Differences in pneumococcal serotype carriage and serotype detection were tested 129 for using two-way Fisher's exact tests for  $2\times 2$ , or Chi-square for  $3\times 2$  contingency tables. An estimate 130 was considered statistically significant at p<0.05.

131

## 132 **RESULTS**

From the 293 24-month-old children previously reported on<sup>27</sup> for pneumococcal carriage detection in their nasopharyngeal samples, 288 (98%) matching saliva samples were available for inclusion in the current study. Results summarised in Table 1 depict differences in pneumococcal carriage detection between the two sample types and diagnostic methods (culture vs. molecular). Here, we report on the sensitivity of each method, defined as the number of carriage events detected by each method, over the total number of carriage events detected by all methods combined.

139

140 Pneumococcal carriage detected by culture

Overall, culture-detected carriage rates were in line with contemporary rates reported by others<sup>14,32,33</sup>, with a relatively high sensitivity of nasopharyngeal carriage detection (0.74). Isolation of live pneumococci from saliva at the initial culture step was virtually impossible due to abundant polymicrobial growth on plates selective for pneumococcus<sup>22,23</sup>, thus the sensitivity of pneumococcal carriage detection by culturing saliva at the primary diagnostic step was null.

146

#### 147 Pneumococcal carriage detected in culture-enriched samples by qPCR

148 Testing culture-enriched samples with qPCR significantly increased pneumococcal detection as 149 compared with culture detection. Testing culture-enriched nasopharyngeal samples by the molecular 150 method was the most sensitive method of carriage detection (0.85) and identified significantly more 151 carriers than testing culture-enriched saliva samples with qPCR (187/288, 65% versus 155/288, 54%; 152 p < 0.001). Nonetheless, saliva significantly contributed to the overall carriage rate detected compared 153 to testing nasopharyngeal swabs alone (219 versus 187, p<0.005). Importantly, there was no 154 difference between the prevalence of carriage detected by testing saliva by qPCR compared with the 155 gold standard culture of nasopharyngeal swabs (155 versus 161, p=0.68).

156

Overall, 219/288 (76%) children were positive for pneumococcus when results of all methods applied
were combined.

159

# 160 Effect of sample type and testing method on pneumococcal serotype detection

Since we report here for the first time on pneumococcal carriage detection using saliva of children, we compared this data to the previously described nasopharyngeal serotype carriage data<sup>27</sup>, detected by either the recommended culture-based approach or by testing culture-enriched nasopharyngeal samples using molecular methods (Table S1).

165

As compared to culture-based pneumococcal detection in nasopharyngeal samples, application of molecular methods to saliva detected significantly more carriers of serotypes 11A/D (19/161, 12% versus 33/155, 21%; p=0.033), 19A (25/161, 16% versus 39/155, 25%; p=0.036) and PCV13-VTs overall (35/161, 22% versus 50/155, 32%; p=0.042) (Figure 1A). However, when both sample types were tested by qPCR, there were no differences in the carriage frequencies of serotypes between

171 nasopharyngeal or saliva samples (Figure 1B). Moreover, there was a strong correlation between the 172 frequency of a serotype detected in nasopharyngeal samples by culture and its frequency of detection 173 in saliva by qPCR (rho=0.845; p<0.001), which was even stronger when results of carriage detection 174 with molecular methods for nasopharyngeal and saliva samples were compared (rho=0.849, 175 p<0.0001).

176

177 With similar rates of overall pneumococcal carriage detection in both nasopharyngeal and saliva 178 samples collected from children, we were interested in the benefit of each sample type for its 179 contribution to serotype detection. Therefore, to investigate the additive effect of samples obtained 180 from different niches on serotype detection in children, we re-analysed the serotyping data, excluding 181 children who were positive for the same serotype in both niches. As compared to culture detection in 182 nasopharyngeal samples, testing saliva with qPCR detected significantly higher carriage of serotypes 183 16F (0/161, 0% versus 5/155, 3%; p=0.027) and 19A (5/161, 3% versus 16/155, 29%; p=0.012; 184 respectively) (Figure 2A). When both sample types were tested by qPCR, there were no significant 185 differences in additional serotypes detected by either sample type (Figure 2B).

186

### 187 DISCUSSION

188 The current culture-based recommendation for detecting pneumococcal carriage is becoming more frequently challenged<sup>18,23-25,34-36</sup>. While culture-independent methods improve the sensitivity of 189 190 carriage detection in nasopharyngeal samples from both children<sup>30,37,38</sup> and adults<sup>23-26,39</sup>, we have 191 also demonstrated improved sensitivity when these methods are applied to alternative respiratory samples from adults<sup>23-25</sup>. Therefore, in the current study, we conducted a direct comparison of 192 193 nasopharyngeal swab and saliva samples collected from 24-month-old children, for their sensitivity for 194 pneumococcal detection when processed by culture and molecular methods; nasopharyngeal 195 sampling proved superior in children.

196

While nasopharyngeal swabs were optimal for overall detection of pneumococcal carriage in children, saliva significantly contributed to the overall carriage rate (219 total carriers detected versus 187 carriers detected by nasopharyngeal swabs alone, p<0.005, and 155 by saliva alone). For serotype carriage detection however, neither nasopharyngeal nor saliva samples were superior when all

medRxiv preprint doi: https://doi.org/10.1101/2023.06.26.23288970; this version posted June 27, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

201 samples were processed by the molecular method. This suggests to us that results for serotype 202 distribution generated using saliva are equally representative to results generated with the current 203 gold standard method of conventional culture of nasopharyngeal swabs in children. It should be noted 204 that culture-enrichment can enhance carriage detection in low density carriers or of secondary (or 205 lesser) serotypes co-carried in a sample when serotype surveillance is being considered. The 206 differences between serotypes detected in saliva compared to serotypes cultured from 207 nasopharyngeal swabs were likely due to failure of colony picking during culture to detect co-carriage of less abundant strain(s)<sup>40</sup>. Importantly, overall serotype detection in saliva samples correlated well 208 209 with qPCR-detection in nasopharyngeal swabs. Hence, molecular testing of saliva samples holds 210 potential for improving surveillance of pneumococcal carriage, providing additional insight into 211 pneumococcal carriage compared to sampling the nasopharynx alone or providing a means to reduce 212 the burden of study protocols through simplified sample collection. Additionally, with little-to-no 213 discomfort from non-intrusive collection, saliva sampling is generally better tolerated compared to nasopharyngeal swabbing encouraging greater adherence to sampling routines<sup>23</sup>, while reducing the 214 215 number of participants or samples lost due to testing aversion and refusing of sample collection<sup>23</sup>. 216 This makes saliva particularly suitable for longitudinal studies.

217

218 The vast majority of epidemiological surveillance studies of pneumococcal carriage are descriptive, 219 based on qualitative results of carriage detection and focus on serotype distribution. They are usually 220 solely aimed at monitoring the disappearance of VTs and the emergence of NVTs. Future vaccines 221 may transcend pneumococcal serotypes, with vaccines protecting against all pneumococci, 222 independent of capsular polysaccharide expressed. In this instance, while determining serotype-223 specific carriage may be only a secondary interest, accurate measures of overall pneumococcus in its 224 ecological niche (the presence and density of all serotypes combined) will remain essential for 225 monitoring vaccine effects and establishing study endpoints. More complex studies, with repeated 226 sampling events, are required for better understanding of carriage dynamics (rates of acquisition and 227 clearance, episode length) in both carriage and disease and in children versus adult populations.

228

229 With the increasing availability of more sensitive detection methods, it is again being reported that as 230 in the early studies, pneumococcal carriage can be long-lasting, and that co-carriage of multiple

231 serotypes is common. Longitudinal carriage of serotypes increases the risk of transmission, but also 232 provides opportunities for intra- and inter-species genetic recombination. While findings from this and 233 previous studies suggest to us that no single sample type should be considered as universally 234 superior for pneumococcal carriage detection across all age groups, collecting saliva from children -235 whether alone or in addition to nasopharyngeal swabs - could be considered as a quick, non-invasive 236 option for enhanced detection with greater serotype carriage. If strain isolation is not of critical 237 importance, the two sample types could be merged and tested as one. Moreover, sampling saliva 238 may have an even greater benefit in broader studies for its potential to also be tested for other upper 239 respiratory tract commensals or pathogens, such as meningococci<sup>41,42</sup>, as well as for antibody 240 responses.

- 241
- 242

## 243 DECLARATIONS

244 Conflict of Interest. ALW has received consulting and/or advisory board fees from Pfizer, RADx, 245 Diasorin, PPS Health, Co-Diagnostics, Filtration Group, and Global Diagnostic Systems for work 246 unrelated to this project, and is Principal Investigator on research grants with Pfizer, Merck, Flambeau 247 Diagnostics, Tempus Labs, and The Rockefeller Foundation to Yale University. MAvH declares to 248 have received research grants from Pfizer. EAMS declares to have received research grants from 249 Pfizer and GSK and fees paid to the institution for advisory boards and participation in independent 250 data monitoring committees for Pfizer and GSK. KT declares to have received research grants from 251 Pfizer and GSK and fees for advisory boards for Pfizer, all paid to the home institution. All other 252 authors report no potential conflicts.

253

Funding. The work was funded by the Dutch Ministry of Health. Unrestricted grant support for molecular microbiology was provided by Pfizer (the Netherlands), through investigator-initiated research grants (WS2312079 and WS2312119 to EAMS and KT).

257

Acknowledgements. We gratefully acknowledge the participating families for their time and commitment to the study. We thank all members of the research team of the Spaarne Gasthuis, the laboratory staff of Regional Laboratory of Public Health, Haarlem, the Netherlands and the

- 261 cooperating institutes for their dedication and work which made this project possible. In particular, we
- 262 would like to thank Astrid Bosch for assistance with sample collection and Lidewij Rümke and Jody
- 263 van Engelsdorp Gastelaars for laboratory assistance.
- 264
- 265 Authors' contributions. ALW, NR, EAMS and KT had the idea and initiated the study. AJWM, NR,
- 266 EAMS and KT wrote the study protocols. ALW, AJWM and MAvH managed the study and collected
- the data. ALW was responsible for and performed the assays. ALW and KT analysed and interpreted
- the data. ALW, EAMS and KT drafted the manuscript. All authors amended and commented on the
- 269 final manuscript.
- 270

# 271 **REFERENCES**

- Simell, B. *et al.* The fundamental link between pneumococcal carriage and disease. *Expert review of vaccines* 11, 841–855 (2012).
- Mitchell, A. M. & Mitchell, T. J. Streptococcus pneumoniae: virulence factors and variation. *Clinical Microbiology and Infection* 16, 411–418 (2010).
- 3. Ganaie, F. *et al.* A new pneumococcal capsule type, 10D, is the 100th serotype and has a large cps
  fragment from an oral streptococcus. *MBio* 11, (2020).
- Whitney, C. G. *et al.* Decline in Invasive Pneumococcal Disease after the Introduction of Protein–
   Polysaccharide Conjugate Vaccine. *New England Journal of Medicine* **348**, 1737–1746 (2003).
- Lexau, C. A. *et al.* Changing epidemiology of invasive pneumococcal disease among older adults in
   the era of pediatric pneumococcal conjugate vaccine. *JAMA* 294, 2043–2051 (2005).
- Wagenvoort, G. H. J. *et al.* Invasive pneumococcal disease: Clinical outcomes and patient
   characteristics 2–6 years after introduction of 7-valent pneumococcal conjugate vaccine compared to
   the pre-vaccine period, the Netherlands. *Vaccine* 34, 1077–1085 (2016).
- Flasche, S. *et al.* Effect of pneumococcal conjugate vaccination on serotype-specific carriage and
   invasive disease in England: a cross-sectional study. *PLoS medicine* 8, e1001017 (2011).
- Reinert, R., Jacobs, M. R. & Kaplan, S. L. Pneumococcal disease caused by serotype 19A: review of
   the literature and implications for future vaccine development. *Vaccine* 28, 4249–4259 (2010).
- 289
  9. Knol, M. J. M. J. *et al.* Invasive pneumococcal disease 3 years after introduction of 10-valent pneumococcal conjugate vaccine, the Netherlands. *Emerging Infectious Diseases* 21, 2040–2044
  (2015).
- Lipsitch, M. Vaccination against colonizing bacteria with multiple serotypes. *Proceedings of the National Academy of Sciences of the United States of America* 94, 6571–6576 (1997).
- Zhou, J., Enright, M. C. & Spratt, B. G. Identification of the major Spanish clones of penicillin-resistant
   pneumococci via the Internet using multilocus sequence typing. *Journal of clinical microbiology* 38,
   977–986 (2000).
- Weinberger, D. M., Malley, R. & Lipsitch, M. Serotype replacement in disease after pneumococcal
   vaccination. *Lancet* 378, 1962–1973 (2011).

Hanage, W. P. *et al.* Evidence that pneumococcal serotype replacement in Massachusetts following
 conjugate vaccination is now complete. *Epidemics* 2, 80–84 (2010).

- 301 14. Bosch, A. A. T. M. *et al.* Nasopharyngeal carriage of Streptococcus pneumoniae and other bacteria in
   302 the 7th year after implementation of the pneumococcal conjugate vaccine in the Netherlands. *Vaccine* 303 34, 1–9 (2015).
- van Deursen, A. M. M. *et al.* Invasive pneumococcal disease and 7-valent pneumococcal conjugate
   vaccine, the Netherlands. *Emerging infectious diseases* 18, 1729–1737 (2012).
- 306 16. Scott, J. R. *et al.* Impact of more than a decade of pneumococcal conjugate vaccine use on carriage
   307 and invasive potential in Native American communities. *J. Infect. Dis.* 205, 280–288 (2012).
- Weinberger, D. M. *et al.* Relating Pneumococcal Carriage Among Children to Disease Rates Among
   Adults Before and After the Introduction of Conjugate Vaccines. *American Journal of Epidemiology* **183**, 1055–1062 (2016).
- 311 18. Satzke, C. *et al.* Standard method for detecting upper respiratory carriage of Streptococcus
   312 pneumoniae: Updated recommendations from the World Health Organization Pneumococcal Carriage
   313 Working Group. *Vaccine* **32**, 165–179 (2013).
- Heffron, R. Epidemiology. in *Pneumonia with special reference to pneumococcus lobar pneumonia* Epidemiology 258-394 (Oxford University Press, 1939).
- Krone, C. L., van de Groep, K., Trzciński, K., Sanders, E. A. M. & Bogaert, D. Immunosenescence and
   pneumococcal disease: an imbalance in host–pathogen interactions. *The Lancet Respiratory Medicine* 2600, 1–13 (2013).
- Webster, L. T. & Hughes, T. P. The epidemiology of pneumococcus infection: the incidence and
   spread of pneumococci in the nasal passages and throats of healthy persons. *The Journal of Experimental Medicine* 53, 535–552 (1931).
- Wyllie, A. L. *et al.* Streptococcus pneumoniae in saliva of Dutch primary school children. *PLoS One* 9, e102045 (2014).
- 324 23. Krone, C. L. *et al.* Carriage of Streptococcus pneumoniae in Aged Adults with Influenza-Like-Illness.
   325 *PLoS One* **10**, e0119875 (2015).
- 326 24. Trzciński, K. *et al.* Superiority of trans-oral over trans-nasal sampling in detecting Streptococcus
   327 pneumoniae colonization in adults. *PLoS One* **8**, e60520 (2013).
- Wyllie, A. L. *et al.* Molecular surveillance on Streptococcus pneumoniae carriage in non-elderly adults;
  little evidence for pneumococcal circulation independent from the reservoir in children. *Sci. Rep.* 6,
  34888 (2016).
- Branche, A. R. *et al.* Effect of prior vaccination on carriage rates of Streptococcus pneumoniae in older
   adults: A longitudinal surveillance study. *Vaccine* 36, 4304–4310 (2018).
- Wyllie, A. L. *et al.* Molecular surveillance of nasopharyngeal carriage of Streptococcus pneumoniae in
  children vaccinated with conjugated polysaccharide pneumococcal vaccines. *Sci. Rep.* 6, 23809
  (2016).
- Bogaert, D. *et al.* Pneumococcal conjugate vaccination does not induce a persisting mucosal IgA
   response in children with recurrent acute otitis media. *Vaccine* 23, 2607–2613 (2005).
- 29. Carvalho, M. da G. S. *et al.* Evaluation and improvement of real-time PCR assays targeting lytA, ply,
  and psaA genes for detection of pneumococcal DNA. *J. Clin. Microbiol.* 45, 2460–2466 (2007).

30. Azzari, C. *et al.* Realtime PCR is more sensitive than multiplex PCR for diagnosis and serotyping in 341 children with culture negative pneumococcal invasive disease. *PloS one* **5**, e9282 (2010).

- 342 31. Pimenta, F. C. *et al.* Sequential Triplex Real-Time PCR Assay for Detecting 21 Pneumococcal
   343 Capsular Serotypes That Account for a High Global Disease Burden. *Journal of Clinical Microbiology* 344 **51**, 647–652 (2013).
- 345 32. Regev-Yochay, G. *et al.* Nasopharyngeal carriage of Streptococcus pneumoniae by adults and
  346 children in community and family settings. *Clinical infectious diseases : an official publication of the*347 *Infectious Diseases Society of America* **38**, 632–639 (2004).
- 34. Hamaluba, M. *et al.* A cross-sectional observational study of pneumococcal carriage in children, their
  parents, and older adults following the introduction of the 7-valent pneumococcal conjugate vaccine. *Medicine* 94, e335 (2015).
- 34. Satzke, C. *et al.* The PneuCarriage project: a multi-centre comparative study to identify the best
  serotyping methods for examining pneumococcal carriage in vaccine evaluation studies. *PLoS Med.*12, e1001903 (2015).
- 35. Adler, H. *et al.* Pneumococcal colonization in healthy adult research participants in the conjugate
  vaccine era, United Kingdom, 2010–2017. *The Journal of Infectious Diseases* (2019)
  doi:10.1093/infdis/jiz034.
- 357 36. Miellet, W. R., Almeida, S. T., Trzciński, K. & Sá-Leão, R. Streptococcus pneumoniae carriage studies
  in adults: Importance, challenges, and key issues to consider when using quantitative PCR-based
  approaches. *Front. Microbiol.* 14, 1122276 (2023).
- 360 37. Carvalho, M. D. G. *et al.* Revisiting Pneumococcal Carriage by Use of Broth Enrichment and PCR
   361 Techniques for Enhanced Detection of Carriage and Serotypes. *Journal of Clinical Microbiology* 48, 1611–1618 (2010).
- 363 38. van den Bergh, M. R. *et al.* Effects of the 10-valent pneumococcal nontypeable Haemophilus
  364 influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: a
  365 randomized controlled trial. *Clinical infectious diseases : an official publication of the Infectious*366 *Diseases Society of America* 56, e30-9 (2013).
- 367 39. Ansaldi, F. *et al.* Carriage of Streptoccoccus pneumoniae in healthy adults aged 60 years or over in a
   368 population with very high and long-lasting pneumococcal conjugate vaccine coverage in children:
   369 rationale and perspectives for PCV13 implementation. *Hum. Vaccin. Immunother.* 9, 614–620 (2013).
- 40. Huebner, R. E., Dagan, R., Porath, N., Wasas, A. D. & Klugman, K. P. Lack of Utility of Serotyping
  Multiple Colonies for Detection of Simultaneous Nasopharygeal Carriage of Different Pneumococcal
  Serotypes. *The pediatric infectious disease journal* **19**, 1017–1020 (2000).
- Rodrigues, F. *et al.* Viable Neisseria meningitidis is commonly present in saliva in healthy young
  adults: Non-invasive sampling and enhanced sensitivity of detection in a follow-up carriage study in
  Portuguese students. *PLOS ONE* **14**, e0209905 (2019).
- 42. Miellet, W. R. *et al.* Detection of Neisseria meningitidis in saliva and oropharyngeal samples from
  college students. *Sci. Rep.* **11**, 23138 (2021).

379 Table 1. Sensitivity of pneumococcal carriage detection in nasopharyngeal and saliva samples

380 collected from PCV7-vaccinated 24-month-old children using conventional and molecular diagnostic

381 methods.

	<b>24-month-olds (n=288)</b> <sup>27</sup>		
Detection method	Carriage	Sensitivity	
Culture			
Nasopharyngeal	161 (60%)	0.74	
Saliva	ND <sup>a</sup>	0	
qPCR			
Nasopharyngeal	187 (65%) <sup>#</sup>	0.85*	
Saliva	155 (54%)	0.71	
Overall	219 (76%) <sup>##</sup>	1	

<sup>a</sup>ND, not detectable by culture due to abundant polymicrobial growth on culture-plate


<sup>#</sup>p<0.05, <sup>##</sup>p<0.001 (Fisher's exact test), significantly more carriers detected by this approach as

384 compared to the gold standard method of culture of nasopharyngeal swab (top row)


385 \*method significantly more sensitive in carriage detection (p<0.05) than any other tested in the 386 particular study group

387

388 FIGURES









# 391 (B)

392 Figure 1. Carriage frequency of pneumococcal serotypes detected in nasopharyngeal and 393 saliva samples from 24-month-old children, when tested by conventional culture or molecular 394 methods. Graphs depict the correlation between the overall carriage frequency of serotypes (from the 395 subset targeted by qPCR), as detected by (A) culture or (B) molecular methods applied to 396 nasopharyngeal swabs compared to the overall carriage frequency of the corresponding serotype 397 when saliva samples were tested by qPCR. The frequency of carriage was calculated for each 398 serotype by the total number of samples testing positive for particular serotype by either the Quellung 399 or molecular methods, over the total number of pneumococcal carriers detected for each study group. 400 Serotypes not detected by only one of the methods were assigned a value of 0.5 x the fraction 401 representing a single carrier. Serotypes not detected by both methods were excluded from correlation 402 calculations. Font colour indicates serotypes targeted by PCV7 (orange), PCV10 (green), PCV13 403 (blue) or NVTs (black). Asterisks depict serotypes which differed significantly (p<0.05) in frequency of 404 carriage between sample types.





407 (I

408 Figure 2. Investigating the additive effect of testing samples obtained from different niches on 409 the frequency of pneumococcal serotypes detected in 24-month-old children. Graphs depict 410 serotype carriage frequency in pneumococcal carriers who tested positive for a specific serotype in 411 only one sample type; individuals who were positive for the same serotype in both sample types were 412 excluded from analysis. The frequency of carriage was calculated for each serotype by the total 413 number of samples testing positive for that particular serotype by either the Quellung or molecular 414 methods, over the total number of pneumococcal carriers detected by that method. When a serotype 415 was detected by only one of the methods, for the method it was not detected by, it was assigned a 416 value of 0.5 x the fraction representing a single carrier. Serotypes not detected by both methods were 417 excluded from correlation calculations. While (A) significantly higher carriage frequencies of serotypes 418 16F and 19A were detected when saliva was tested by qPCR as compared to the gold standard 419 culture-based method (p<0.05), (B) no serotype was detected more frequently by either sample type 420 when samples were tested by qPCR. Font colour indicates serotypes targeted by PCV7 (orange), 421 PCV10 (green), PCV13 (blue) or NVTs (black). Asterisks depict serotypes which differed significantly 422 (p<0.05) in frequency of carriage between sample types.